Preview Newsletter
XARELTO Media Monitoring – Week of 12-11-15
-
Xarelto Lawsuit Alleges Blood-Thinner Caused Fatal Uncontrollable Internal Bleeding
Dec 5, 2015 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on another wrongful death lawsuit which was filed in Florida against Xarelto manufacturers and distributors. The lawsuit claims that both manufacturers and distributors neglected to properly warn consumers of the significant dangers associated with the blood-thinning drug, which allegedly caused the plaintiff’s husband to die from an uncontrollable episode of internal bleeding. -
Xarelto Lawsuit Alleges Drug Caused Texas Woman’s Internal Bleeding Episode
Dec 7, 2015 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on a lawsuit filed in the Eastern District of New York which involves a Texas woman who alleges that Xarelto manufacturers Janssen Pharmaceuticals and Bayer AG neglected to properly warn consumers about the significant risks associated with the blood thinner. Her complaint was filed under number 1:14-cv-04524 in a federal court. -
Xarelto Lawsuit From Vermont Alleges Drug Caused Father’s Fatal Bleedout
Dec 8, 2015 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on a lawsuit filed in Vermont against the manufacturers of blood-thinning drug Xarelto: Bayer AG and Janssen Pharmaceuticals (a subdivision of Johnson & Johnson). This particular complaint was filed under case number 2:14-cv-00159-CR in a Vermont federal court by a young woman whose father died from uncontrollable bleeding complications. The lawsuit alleges that anticoagulant Xarelto caused the man’s uncontrollable bleeding and death. -
Xarelto Lawsuit Plaintiff Alleges Drug Caused Dangerous Bleeding Episode
Dec 8, 2015 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com shares details concerning another lawsuit which was filed against blood-thinning drug Xarelto, as well as manufacturers Bayer AG and Johnson & Johnson. The suit alleges that defendants fraudulently misrepresented the dangers and benefits connected with their drug. This particular filing involved a detailed, 32-count complaint which was filed on October 13th in St. Clair County Circuit Court. -
Xarelto Lawsuit Plaintiffs Seek Significant Compensation For Life-Threatening Injuries
Dec 10, 2015 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on another lawsuit filed against blood-thinner Xarelto. This particular lawsuit was filed on October 5th of 2015 in the United States District Court for the Southern District of Ohio. The complaint was filed by a husband and wife who live in Morrow County, Ohio. Together, they have alleged that Xarelto manufacturers Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson) are liable for serious and life-threatening injuries experienced by the wife, and they are seeking over $50,000 for these injuries. -
Xarelto Lawsuit News: Xarelto Trial Results Questioned Due To Defective Device
Dec 10, 2015 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com details reports from Reuters on the latest news surrounding blood-thinner Xarelto. At this time, it has been learned that both United States and European drug regulators are researching whether a defective blood clotting test device may have affected the outcome of trial results involving Xarelto manufactured by Bayer AG. -
Xarelto Mass Tort Lawsuits In Philadelphia, PA Sees Lawsuit Volume Increases
Dec 10, 2015 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com announces additional developments showing an increase in the lawsuits filed against anticoagulant Xarelto in Philadelpha, Pennsylvania’s mass tort group. This group was created following a motion to consolidate the mounting cases, which are said to have surpassed 500. Federally, these cases are joined by over 1,800 Xarelto bleeding lawsuit cases consolidated with multidistrict litigation number 2592 in the Eastern District of Louisiana. Plaintiffs involved in each case grouping similarly allege that blood-thinner Xarelto can cause serious uncontrollable bleeding episodes. -
Xarelto Lawsuit: ProLegal Attorneys And Lawyers Offer Free Legal Consultation For Sufferers Of Blood Thinner Xarelto Side Effects
Dec 11, 2015 | ProLegal Attorneys
By James Hill
Hundreds of patients or their families have filed lawsuits against the makers of Xarelto after suffering severe, and sometimes fatal, bleeding. Plaintiffs claim that Xarelto manufacturers Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson) and Bayer did not provide adequate warnings concerning the risk of uncontrolled bleeding, and may have put thousands of people at risk. -
Xarelto side effects – uncontrollable bleeding kills another man
Dec 5, 2015 | Xarelto Lawsuit Information
Victims of the infamous blood-thinner Xarelto keep mounting up. A new Xarelto lawsuit has been filed by a man in Georgia, Louisiana against Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson), the pharmaceutical companies that manufactured the dangerous Novel Oral Anticoagulant (NOAC). The plaintiff accuses the Big Pharma of the death of his father, who allegedly died because of an uncontrollable bleeding event consequent to the use of Xarelto. -
An introduction to pharmaceutical mass tort litigation: A special look at Xarelto
Dec 7, 2015 | NJ.com
By H. Matthew Taylor
I am commonly asked by clients, what is the difference between a "Class Action" and a "Mass Tort" lawsuit? For those unaware, Class Action is a legal term used to identify a group of individuals, designated as a "class," which all have a common interest in the outcome of a litigation. The Class Action is a procedural mechanism created under the Federal Rules of Civil Procedure and New Jersey Court Rule 4:32-1 that allows for global resolution of common claims. -
Xarelto Lawsuit: Blood Thinner Caused Man’s Death
Dec 7, 2015 | Top Class Actions
By Paul Tassin
A plaintiff from Oklahoma has joined the Xarelto multidistrict litigation, representing himself and the estate of his late spouse. -
Xarelto Clinical Trial Data Questioned Due to Use of Faulty Device
Dec 7, 2015 | AboutLawsuits.com
By Irvin Jackson
Serious questions have been raised about the validity of the clinical trials that led to approval of the controversial anticoagulant Xarelto, which is the subject of thousands of lawsuits filed on behalf of individuals who have suffered severe and uncontrollable bleeds. -
Xarelto Lawsuits’ Similarities To Pradaxa Lawsuits Encourage Plaintiffs
Dec 8, 2015 | Mass Tort Nexus
By Larry Bodine
BloodThinnerHelp.com reports on similarities between Xarelto and Pradaxa lawsuits, which have helped to give plaintiffs involved in current Xarelto lawsuits hope as they pursue justice. Xarelto lawsuit filings have recently exploded. -
Xarelto Lawsuit Claims Man Suffers Brain Bleed
Dec 9, 2015 | Top Class Actions
By Melissa LaFreniere
A Xarelto lawsuit claims the blood thinner caused a life-threatening brain hemorrhage after the plaintiff took the drug for three months. -
Xarelto History: What you need to know
Dec 9, 2015 | Your Xarelto Attorneys
In 2011, the U.S. Food and Drug Administration (FDA) announced that it approved the anti-clotting drug Xarelto® (rivaroxaban) to reduce the risk of stroke in people who have abnormal heart rhythm, or non-valvular atrial fibrillation. The FDA also approved Xarelto® to reduce the risk of blood clots, deep vein thrombosis, and pulmonary embolism following knee or hip replacement surgery. Xarelto® is manufactured by Janssen Pharmaceuticals, Inc., which is a subsidiary of Johnson & Johnson. Xarelto® is also co-marketed with Bayer AG.Safety of Xarelto® -
Xarelto Side Effects & Lawsuit Information
Dec 11, 2015 | Active Health News
Xarelto is a blood-thinning drug, or anticoagulant. The U.S. Food and Drug Administration (FDA) approved Xarelto in July 2011, and its sales have steadily grown since then. While bleeding is a common complication associated with anticoagulants, it has been alleged that Xarelto is more dangerous than traditional blood thinners because no antidote exists to reverse its blood-thinning side effects.
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Plaintiff Attorney Press Releases
Plaintiff Attorney Blog Posts
Full Text of Articles Below
-
Xarelto Lawsuit Alleges Blood-Thinner Caused Fatal Uncontrollable Internal Bleeding
Dec 5, 2015 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on another wrongful death lawsuit which was filed in Florida against Xarelto manufacturers and distributors. The lawsuit claims that both manufacturers and distributors neglected to properly warn consumers of the significant dangers associated with the blood-thinning drug, which allegedly caused the plaintiff’s husband to die from an uncontrollable episode of internal bleeding.
Xarelto came on the market after FDA approval in 2011 as a revolutionary new type of blood thinner. Traditional blood thinners required special diets and regular monitoring by doctors, but Xarelto had none of these restrictions. Unfortunately, however, a common oversight was that the drug also had no corresponding antidote. Today, this fact makes Xarelto allegedly one of the most dangerous blood thinners on the market.
Having no corresponding antidote simply means that if a patient is taking Xarelto and begins to bleed, doctors have no way of controlling that bleed and making it clot. In these cases, the doctors have to resort to extreme life-saving measures such as blood transfusions in an attempt to keep the patient alive.
Traditional blood thinners offer an antidote in vitamin K, (which is also why they require a special diet). If a patient using a traditional blood thinner begins to bleed, physicians can treat them with vitamin K which will counter the effects of the medication and allow their blood to clot. This important detail can mean the difference between life and death for some.
Due to these dangers, Xarelto is now the subject of nearly 2,000 federal lawsuits and about 500 consolidated in a Philadelphia mass tort grouping. This particular lawsuit was initially filed in the U.S. District Court for the Southern District of Florida under case number 9:14-cv-80831. Details of the complaint state that the widow’s husband was using Xarelto due to his atrial fibrillation condition, in order to prevent blood clots. He suffered from a subdural hemorrhage while on Xarelto (a brain bleed) and died after physicians were unable to control the bleed.
As all of these cases await trial, plaintiffs expect that other lawsuits against the drug will continue to be filed. During this time, Attorney Joseph Osborne is working to ensure that everyone who has been negatively affected by the drug has the opportunity to evaluate their legal rights. Some of these individuals and their families may be entitled to legal action and significant compensation. Attorney Osborne is offering complimentary consultations for those involved.
To request more information on Xarelto bleeding lawsuits, or to ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2766311
-
Xarelto Lawsuit Alleges Drug Caused Texas Woman’s Internal Bleeding Episode
Dec 7, 2015 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on a lawsuit filed in the Eastern District of New York which involves a Texas woman who alleges that Xarelto manufacturers Janssen Pharmaceuticals and Bayer AG neglected to properly warn consumers about the significant risks associated with the blood thinner. Her complaint was filed under number 1:14-cv-04524 in a federal court.
Details of the suit explain that the plaintiff was prescribed Xarelto to treat her atrial fibrillation condition, which can sometimes be the cause of blood clots and strokes. Blood thinners are commonly prescribed in these cases as a preventative measure. In this case, however, the woman took the blood thinner just 5 months before suffering from a life-threatening internal bleed. The complaint notes that this bleed left the woman with long-term health effects which will require specialized care, although it does not specify these injuries further.
Xarelto was released to the market after its 2011 U.S. Food and Drug Administration approval. Because it did not require regular monitoring and adjustments by physicians or a special diet as other blood thinners did, it was initially regarded as a revolutionary new option. This excitement, however, was short lived, as consumers began to realize Xarelto was released to the market without a corresponding antidote. This discovery prompted many to refer to the drug as the most dangerous blood thinner currently on the market.
The lack of antidote means that if a patient using Xarelto is injured and begins to bleed, doctors will be unable to counter the effects of the drug and get their blood to clot. In these cases, doctors must resort to extreme life-saving measures, such as blood transfusions in an attempt to keep the patient alive. Additionally,when bleeds lead to the development of pools of blood in the brain or spine area, doctors may have to operate in order to drain this blood and release this pressure.
Patients who use traditional blood thinners, however, have an available antidote in vitamin K. This means that when a patient taking a traditional blood thinner is injured and begins to bleed, doctors can treat them with vitamin K which will counteract the effects of the drug and allow their blood to clot. The antidote for traditional blood thinners can be the difference between life and death.
Currently, Xarelto uncontrollable bleeding lawsuits number around 2,000 cases federally. They have been consolidated to form multidistrict litigation number 2592 and are being overseen by the Honorable Judge Eldon Fallon in the Eastern District of Louisiana. As these cases await preparations for trial, Attorney Joseph Osborne is working to ensure that everyone affected by Xarelto will be able to have the opportunity to evaluate their legal rights. Individuals who used Xarelto and later suffered adverse health effects may be entitled to significant compensation. Attorney Osborne is offering free legal consultations to those involved.
To ask questions, or obtain additional information on Xarelto bleeding lawsuits, please contact Attorney Joseph Osborne by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2767963#ixzz3u2IsiRRc
-
Xarelto Lawsuit From Vermont Alleges Drug Caused Father’s Fatal Bleedout
Dec 8, 2015 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on a lawsuit filed in Vermont against the manufacturers of blood-thinning drug Xarelto: Bayer AG and Janssen Pharmaceuticals (a subdivision of Johnson & Johnson). This particular complaint was filed under case number 2:14-cv-00159-CR in a Vermont federal court by a young woman whose father died from uncontrollable bleeding complications. The lawsuit alleges that anticoagulant Xarelto caused the man’s uncontrollable bleeding and death.
The daughter’s complaint details that her father was prescribed Xarelto in an attempt to treat his atrial fibrillation. This is a fairly common heart condition which often makes the heart beat at a faster rate than normal. Atrial fibrillation can cause blood clots or strokes, so individuals diagnosed with the condition commonly use blood thinners as a preventative measure.
After using Xarelto for just a short time, the plaintiff’s father injured himself and began to bleed. He was rushed to the hospital, where doctors said he had suffered a parenchymal hemorrhage. Due to the active Xarelto in his system, the doctors were unable to control the man’s blood loss or get his blood to clot. They exhausted every attempt to keep him alive, which they were able to do for 6 days before he ultimately passed away.
Due to these circumstances, the daughter’s complaint directly addresses what many other Xarelto lawsuits do: the lack of antidote for the drug. Because Xarelto has no antidote, patients using the drug who begin to bleed have few options. In these circumstances, physicians simply cannot clot the blood, so they have to resort to extreme life saving measures such as surgeries to remove blood pools, or blood transfusions to replace lost blood.
Patients who use traditional blood thinners do not encounter these same issues. Traditional blood thinners have an antidote available in vitamin K. This means that when someone with a traditional blood thinner in their system begins to bleed, physicians can treat them with vitamin K, and this will counter the effects of the drug and allow their blood to clot.
In her complaint, the daughter states that had she and her father been previously aware of these dangerous factors concerning Xarelto, they would have chosen a safer alternative. Many plaintiffs involved in the current Xarelto litigation feel the same way. Lawsuits filed against Xarelto federally now number around 1,800 cases. They have been consolidated to form multidistrict litigation number 2592 in the Eastern District of Louisiana, and will be overseen by Judge Eldon Fallon.
As these cases prepare to go to trial, many expect that their numbers will only continue to rise. Attorney Joseph Osborne is working to ensure that everyone affected has the opportunity to evaluate their legal rights at this time. Those who have used Xarelto and suffered subsequent adverse health effects may be entitled to compensation. Attorney Osborne offers complimentary legal consultations for these individuals.
To request more information concerning Xarelto bleeding lawsuits, or to ask questions, please contact Attorney Joseph Osborne by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2769884#ixzz3u2IP9P1u
-
Xarelto Lawsuit Plaintiff Alleges Drug Caused Dangerous Bleeding Episode
Dec 8, 2015 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com shares details concerning another lawsuit which was filed against blood-thinning drug Xarelto, as well as manufacturers Bayer AG and Johnson & Johnson. The suit alleges that defendants fraudulently misrepresented the dangers and benefits connected with their drug. This particular filing involved a detailed, 32-count complaint which was filed on October 13th in St. Clair County Circuit Court.
The lawsuit’s details allege that these defendants failed to properly warn physicians and medical providers of the significant risk for uncontrollable bleeding that their anticoagulant could cause. Additionally, the plaintiff alleged that defendants actually knowingly exaggerated the benefits of Xarelto in comparison to other blood thinners currently on the market.
Xarelto has become widely considered the most dangerous blood thinner on the market, and has been the subject of over 2,000 lawsuits. Federally filed lawsuits have been consolidated to form multidistrict litigation number 2592, and number around 1,800 cases, while a mass tort group in Philadelphia has consolidated around 500 additional cases.
It is said that plaintiffs consider Xarelto significantly dangerous due to the fact that manufacturers released the drug to market without any corresponding antidote, and have yet to develop one today– years later. This lack of antidote means that when someone using Xarelto becomes injured and bleeds, physicians will be unable to counter the drug’s effects and get the patient’s blood to clot. In these situations, the physicians must resort to life-saving measures such as blood transfusions or surgeries in an attempt to keep the patients alive.
Traditional blood thinners such as warfarin do not have the same issue. If a patient using a traditional blood thinner is injured and begins to bleed, doctors are able to treat them with vitamin K, which counters the drug’s effects and allows their blood to clot, saving the patient from losing too much blood.
The plaintiff in this particular case has had an uncontrollable bleeding episode since using Xarelto–one that will leave them with lasting health issues. Because of this, he is now seeking over $50,000 in compensation, plus coverage of attorney and litigation fees. If he is successful in claiming compensation, he may use this money to cover current and future medical bills due to the injuries he has sustained. His case is filed under St. Clair County Circuit Court number 15-L-581.
Similar lawsuits have been filed against Xarelto across the nation. Since the federal cases were consolidated to form multidistrict litigation, their numbers have continued to rapidly rise. As these cases await trial, it is anticipated that new Xarelto bleeding lawsuits will be filed which will similarly allege that the drug causes an increased risk for uncontrollable bleeding, and that its lack of antidote is dangerous and negligent.
Today, Attorney Joseph Osborne works to ensure that anyone who has suffered adverse health events after using Xarelto will have the opportunity to explore their legal rights. These people may be entitled to significant compensation. Attorney Osborne is offering complimentary legal consultations to those affected.
To request more information on the pending Xarelto litigation, or to ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.fox8live.com/story/30699953/xarelto-lawsuit-plaintiff-alleges-drug-caused-dangerous-bleeding-episode
-
Xarelto Lawsuit Plaintiffs Seek Significant Compensation For Life-Threatening Injuries
Dec 10, 2015 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com reports on another lawsuit filed against blood-thinner Xarelto. This particular lawsuit was filed on October 5th of 2015 in the United States District Court for the Southern District of Ohio. The complaint was filed by a husband and wife who live in Morrow County, Ohio. Together, they have alleged that Xarelto manufacturers Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson) are liable for serious and life-threatening injuries experienced by the wife, and they are seeking over $50,000 for these injuries.
Details found within the complaint explain that the wife was prescribed Xarelto to prevent stroke due to her atrial fibrillation condition, which was chronic. Xarelto was approved in 2011 by the U.S. Food and Drug Administration to be used for this purpose as well as a treatment for people who are undergoing knee and hip replacement surgeries.
In this case, the woman suffered from gastrointestinal bleeding and anemia only two months after beginning to take the drug. She alleges that the injuries have required expensive and lengthy medical treatment, and that even today, she continues to require certain treatments.
Lawsuits similar to this one have recently surged in number. Federally, they number over 1,800 and have been consolidated to form multidistrict litigation number 2592. These cases are being overseen by Judge Eldon Fallon in the Eastern District of Louisiana. Additionally, there is another grouping of Xarelto lawsuits which have been formed into a mass tort in Philadelphia, Pennsylvania. Plaintiffs involved in these cases allege that Xarelto causes serious uncontrollable bleeding episodes, and is especially dangerous due to the fact that it has no available antidote.
Having no antidote means that if a person taking Xarelto begins to bleed, doctors cannot do anything to counter the effects of the drug and allow that person’s blood to clot. In these cases, patients require extreme measures such as surgeries and blood transfusions. Other traditional blood thinners, however, have an available antidote in vitamin K. If a person using a traditional blood thinner begins to bleed, physicians can treat them with vitamin K, which will allow their blood to clot.
As lawsuits continue to grow in number across the nation, Attorney Joseph Osborne is working to ensure that everyone who has been negatively affected by the drug will have the opportunity to explore their legal rights. Those who have used Xarelto and who have subsequently experienced adverse health effects may be entitled to significant compensation. Attorney Osborne is offering these individuals free legal consultations at this time.
To ask questions or request more information about Xarelto bleeding lawsuits, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2772957#ixzz3u2QToXe7
-
Xarelto Lawsuit News: Xarelto Trial Results Questioned Due To Defective Device
Dec 10, 2015 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com details reports from Reuters on the latest news surrounding blood-thinner Xarelto. At this time, it has been learned that both United States and European drug regulators are researching whether a defective blood clotting test device may have affected the outcome of trial results involving Xarelto manufactured by Bayer AG.
Xarelto is now the subject of over 2,000 lawsuits which commonly allege that the blood thinner causes significantly dangerous uncontrollable bleeding episodes in patients. The lawsuits surrounding the drug which were filed federally have been consolidated to form multidistrict litigation number 2592 in the Eastern District of Louisiana.
The new study was planned in order to compare Xarelto with a more traditional blood thinner (warfarin) in overall effectiveness for preventing strokes in patients with atrial fibrillation, (a common irregular heartbeat condition in older individuals). During the study, however, results may have been affected because of a defect in the medical device used.
“Due to the defect, it is now thought that the INR (international normalized ration) device may have impacted the clotting results in some patients in the warfarin group,” the European Medicines Agency stated after the study. They noted that they would publish the study’s results after their investigation into the effects of the defective device were completed.
INR devices measure how fast blood begins to clot. It has been said that the system used for this study was recalled in December of 2014 due to the discovery of some falsely low results.
Plaintiffs involved in Xarelto lawsuits have alleged that Xarelto is currently the most dangerous blood thinner on the market due to the fact that it has no corresponding antidote. If someone using Xarelto becomes injured and bleeds, doctors will be unable to get that person’s blood to clot, and will have to resort to extreme life-saving measures such as surgery or blood transfusions in order to try to save the person’s life.
Individuals taking traditional blood thinners do not have this issue, due to the fact that traditional blood thinners have an available antidote in vitamin K. When these patients begin to bleed, doctors can treat them with vitamin K, which will counter the effects of the drug and allow their blood to clot.
As the cases involved in the Xarelto MDL and Xarelto mass tort grouping await trial, Attorney Joseph Osborne is working to help ensure that everyone who has been negatively affected by Xarelto will be able to explore their legal rights. Anyone who took Xarelto and subsequently suffered from adverse health events may be entitled to compensation. Attorney Osborne is offering free consultations to these individuals.
To request more information regarding Xarelto bleeding lawsuits, or to ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2772958#ixzz3u2QvT6bs
-
Xarelto Mass Tort Lawsuits In Philadelphia, PA Sees Lawsuit Volume Increases
Dec 10, 2015 | BloodThinnerHelp.com
By Joseph Osborne
BloodThinnerHelp.com announces additional developments showing an increase in the lawsuits filed against anticoagulant Xarelto in Philadelpha, Pennsylvania’s mass tort group. This group was created following a motion to consolidate the mounting cases, which are said to have surpassed 500. Federally, these cases are joined by over 1,800 Xarelto bleeding lawsuit cases consolidated with multidistrict litigation number 2592 in the Eastern District of Louisiana. Plaintiffs involved in each case grouping similarly allege that blood-thinner Xarelto can cause serious uncontrollable bleeding episodes.
Litigation for the Xarelto cases is currently in initial pretrial and discovery stages. Those involved expect that as they await trial, these numbers will only continue to grow. Philadelphia’s mass tort cases were consolidated in the Philadelphia Court of Common Pleas, specifically in their Complex Litigation Center. Allegations within the suits are filed against defendants Bayer AG and Janssen Pharmaceuticals, (a subdivision of Johnson & Johnson). Additional claims state that these manufacturers were negligent to release their drug to the market without any corresponding antidote.
Many plaintiffs additionally note the fact that Xarelto was released to the market without any corresponding antidote. Due to this fact, they consider it the most dangerous blood thinner currently on the market. Without an antidote, individuals who are bleeding with Xarelto in their system will be unable to get their blood to clot. In these situations, physicians must result to extreme life-saving measures such as surgeries or blood transfusions.
The lawsuits currently filed in Philadelphia’s mass tort group cite multiple complaints, some of which include internal bleeding and wrongful death. Several of the suits have been filed by families of the victims, as the victims have passed away from uncontrollable bleeding episodes. Plaintiffs are seeking compensation for a range of things, from damages and medical bills to funeral costs and legal fees.
As these case numbers are expected to continue to grow, Attorney Joseph Osborne is currently working to help ensure that individuals involved are all given the opportunity to explore their legal rights. Anyone who has taken Xarelto and has suffered adverse health events that they attribute to the drug may be entitled to significant compensation. Attorney Osborne offers complimentary legal consultations to those affected.
For questions regarding this press release, or to request additional information about the pending Xarelto litigation, please contact Joseph Osborne, Esq. by calling (866) 425-8902.
http://www.wflx.com/story/30718807/xarelto-mass-tort-lawsuits-in-philadelphia-pa-sees-lawsuit-volume-increases
-
Dec 11, 2015 | ProLegal Attorneys
By James Hill
Hundreds of patients or their families have filed lawsuits against the makers of Xarelto after suffering severe, and sometimes fatal, bleeding. Plaintiffs claim that Xarelto manufacturers Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson) and Bayer did not provide adequate warnings concerning the risk of uncontrolled bleeding, and may have put thousands of people at risk.
In 2011, US Food and Drugs Administration (FDA) approved Xarelto to reduce the risk of blood clots, deep vein thrombosis, and pulmonary embolism in patients undergoing knee or hip replacement surgery, but also to reduce the risk of stroke in patients with irregular heartbeat called atrial fibrillation.
Xarelto is a new type of anticoagulant – a medication that prevents blood from clotting. Blood clots that form inside veins or arteries may be dangerous, especially when they travel to the heart, lungs, or brain. For patients with a high risk of blood clots, treatment with blood thinners may be appropriate. Unfortunately, blood thinners can have serious side effects. Too high doses put patients at risk of bleeding to death. While the older blood thinners have antidotes or they can be removed from the blood by dialysis, Xarelto has no antidote and is not affected by dialysis. Therefore, bleeding can not be controlled and may be fatal for patients who take Xarelto.
In 2013, the FDA issued a warning letter to Janssen Pharmaceuticals stating that a print advertisement for Xarelto is false because it minimizes the risks associated with the drug and makes a misleading claim suggesting that dosage adjustments are not necessary with Xarelto. Now, more and more patients injured by Xarelto side effects are filing lawsuits. Victims of Xarelto say they were not adequately warned about the risk of side effects, nor about the fact that Xarelto does not have an antidote and can cause uncontrolled bleeding.
http://www.digitaljournal.com/pr/2773322
-
Xarelto side effects – uncontrollable bleeding kills another man
Dec 5, 2015 | Xarelto Lawsuit Information
Victims of the infamous blood-thinner Xarelto keep mounting up. A new Xarelto lawsuit has been filed by a man in Georgia, Louisiana against Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson), the pharmaceutical companies that manufactured the dangerous Novel Oral Anticoagulant (NOAC). The plaintiff accuses the Big Pharma of the death of his father, who allegedly died because of an uncontrollable bleeding event consequent to the use of Xarelto.
Federal Xarelto bleeding lawsuits kept accruing, reaching over 2,000 total cases in the last few years. All the Xarelto litigations have been consolidated in the Multi-District Litigation (MDL nNumber 2592) in the United States District Court for the Eastern District of Louisiana, in New Orleans, presided over by Judge Eldon Fallon. Additional class action mass tort claims have been formed in Philadelphia, Pennsylvania to speed up the legal proceedings that include several similar allegations against the drug manufacturers. Four cases chosen as the most representative ones will be heard during bellwether trials. The first two trials will be held on February 6, 2017, and March 13, 2017, in the Eastern District of Louisiana; the third on has been scheduled on April 24, 2017, in Mississippi; and the fourth on May 30, 2017, in Texas.
Xarelto is in fact often associated with several cases of internal bleedings and haemorrhages, whose consequence included serious injuries to the patients and, in some instances, even their death. Xarelto has been approved by the Food and Drugs Administration (FDA) for the prevention of blood clots and stroke during atrial fibrillation, and for the treatment and prevention of pulmonary embolism and deep venous thrombosis. However, the absence of a proper antidote makes Xarelto a dangerous medication in the event of an internal bleeding. Once its effects cause and haemorrhage, in fact, there’s no way to revert them as a constant transfusion of fresh platelets or Vitamin K are ineffective.
The complaint number 2:15-cv-00886, was filed on March 20th of 2015, in the state of Louisiana. The patient died after an uncontrollable internal bleeding event, just a few time after being prescribed Xarelto to treat his atrial fibrillation. The patient’s son explained that they had no idea that Xarelto was so dangerous, and that nobody explained them the potential consequences of using this medication. Not knowing this information prevented he and his family to make a properly informed choice about using or not this type or treatment. The lack of a proper safety warning could be considered as negligence from Bayer and Janssen Pharmaceutica.
https://www.xareltocares.com/xarelto/xarelto-side-effects-uncontrollable-bleeding-kills-another-man/
-
An introduction to pharmaceutical mass tort litigation: A special look at Xarelto
Dec 7, 2015 | NJ.com
By H. Matthew Taylor
I am commonly asked by clients, what is the difference between a "Class Action" and a "Mass Tort" lawsuit? For those unaware, Class Action is a legal term used to identify a group of individuals, designated as a "class," which all have a common interest in the outcome of a litigation. The Class Action is a procedural mechanism created under the Federal Rules of Civil Procedure and New Jersey Court Rule 4:32-1 that allows for global resolution of common claims.
On the other hand, the term Mass Tort is generally used to connote mass personal injury and property damage lawsuits that involve related circumstances. Mass Torts are consolidated to permit the court system to manage a large volume of similar, but discrete, claims. Many times it is the varying liability, damages, and procedural issues that make those cases less amenable to Class Action treatment and more suited for Mass Tort treatment.
To summarize, in a Class Action, a complaint is filed on behalf of a small number of named parties alleging an injury on behalf of themselves and other similarly situated individuals whose identities are yet unknown. In a Mass Tort scenario, by contrast, separate complaints are brought by separate, allegedly injured parties, and those matters, if so designated, will be coordinated and handled by a single judge. Mass Tort plaintiffs often have similar injuries; however, their recovery is individualized and dependent upon their own unique set of facts.
Product liability actions filed against the manufacturers of pharmaceutical medications, more often than not, proceed as Mass Torts filed in Federal or State court. An MDL (or Multidistrict Litigation) is the name of a Mass Tort case filed in Federal court. A Mass Tort case filed in New Jersey State court is known as an MCL (or Multicounty Litigation).
By way of example, Stark & Stark is actively handling lawsuits involving the medication Xarelto (otherwise known as rivaroxaban), which is a blood thinner that was approved by the U.S. Food & Drug Administration (FDA) in July 2011 to treat and prevent blood clots in patients who received hip and knee replacements. In November 2011, the approval was expanded to reduce the risk of stroke for any patients with atrial fibrillation, or irregular heartbeat. Millions of people have taken the medication since it entered the market. Unfortunately, since then many of these individuals have experienced severe injuries. It is alleged that Xarelto has caused these injuries, including brain hemorrhaging, hemorrhagic strokes, and gastrointestinal bleeding.
Video: https://www.youtube.com/watch?v=r1neT-LdP3M
Our office is filing Xarelto cases in Federal court for plaintiffs across the country as part of a large Mass Tort action, centralized as MDL 2592. The MDL is pending in the Eastern District of Louisiana and now includes close to 2,000 cases. The judge presiding over the MDL has entered a series of Case Management Orders that have allowed the parties to efficiently manage and conduct the litigation.
Please contact us if you have any questions about the content of this article or wish to speak with an attorney, free of charge, to discuss any claims that you might have against the manufacturers of Xarelto or any other medication.
http://blog.nj.com/stark_stark/2015/12/an_introduction_to_pharmaceuti.html
-
Xarelto Lawsuit: Blood Thinner Caused Man’s Death
Dec 7, 2015 | Top Class Actions
By Paul Tassin
A plaintiff from Oklahoma has joined the Xarelto multidistrict litigation, representing himself and the estate of his late spouse.
Plaintiff Sheldon M. says that his late spouse David started taking Xarelto in November 2012. The next April, David allegedly suffered a hemorrhage that took his life. Sheldon attributes David’s hemorrhage and subsequent death to his course of Xarelto.
Sheldon is now suing Janssen Pharmaceuticals, Johnson & Johnson, Bayer Corporation, and their related companies, all of whom he says are involved in the manufacture or distribution of Xarelto.
Xarelto is an anticoagulant medication made by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. It’s also known by its generic name rivaroxaban.
According to Sheldon’s Xarelto lawsuit, the FDA granted initial approval for Xarelto in July 2011 to reduce the risk of blood clots, deep vein thrombosis, and pulmonary embolism.
In November 2012, additional approval was granted to use Xarelto as a treatment for existing pulmonary embolism and deep venous thrombosis, and as a long-term treatment to prevent those conditions from recurring.
Sheldon alleges that the defendants failed to properly alert physicians and patients about the risk of Xarelto bleeding. He says that David would not have used Xarelto if the defendants had properly disclosed the risks associated with its use.
The Xarelto lawsuit refers to a promotional website for Xarelto that promotes the drug as not requiring regular blood monitoring or dietary restrictions. He says the website also promotes Xarelto as needing only once-daily dosing.
Sheldon alleges that through this website and other marketing materials, the defendants misled patients and physicians as to the need to monitor any patient taking a blood thinning agent.
The plaintiff says that in June 2013 the FDA sent defendants a letter challenging a print ad for Xarelto that appeared in the January/February issue of WebMD magazine. The FDA said that the ad was “false or misleading because it minimizes the risks associated with Xarelto® and makes a misleading claim,” Sheldon says.
The FDA also took issue with the ad’s statement “And there are no dosage adjustments,” which apparently conflicted with Xarelto’s FDA-approved labeling, according to Sheldon.
Sheldon is seeking compensation to cover medical and other expenses, the loss of the prospective income to David’s estate, and an award of punitive damages. Sheldon is also asking the court to award damages reflecting the loss of his relationship with David, including companionship, support and services, as well as Sheldon’s own mental pain and suffering that followed from David’s illness and death.
Sheldon’s claim is part of the Xarelto multidistrict litigation that is now going on in a federal court in Louisiana. This multidistrict litigation, or MDL, is a consolidation of several individual Xarelto lawsuits before a single judge, who oversees pretrial procedures.
The federal court system uses the MDL procedure to more efficiently handle large numbers of similar claims, such as occur often in large-scale pharmaceutical products liability litigation.
The Xarelto Bleeding Lawsuit is Case No. 2:15-CV-01059-EEF-MBN and MDL No. 2592 in the U.S. District Court for the Eastern District of Louisiana.
http://topclassactions.com/lawsuit-settlements/lawsuit-news/237725-surviving-spouse-files-xarelto-lawsuit/
-
Xarelto Clinical Trial Data Questioned Due to Use of Faulty Device
Dec 7, 2015 | AboutLawsuits.com
By Irvin Jackson
Serious questions have been raised about the validity of the clinical trials that led to approval of the controversial anticoagulant Xarelto, which is the subject of thousands of lawsuits filed on behalf of individuals who have suffered severe and uncontrollable bleeds.
In a report published in The BMJ (subscription required) on December 3, researchers warns that a defective device used during the clinical trials may have led to an underestimation of the rate of Xarelto bleeding complications.
The device, the INRatio, by Alere, was used in the ROCKET-AF clinical trials, which compared the rate of bleeding events between Xarelto (rivaroxaban) and Coumadin (warfarin). The device measured the levels of warfarin in patients’ blood and was used to adjust their dosage. However, in December 2014 there was an INRatio recall after it was discovered that some of the devices could return results that were falsely low. The recall came after Alere received nearly 19,000 reports of malfunctions, 14 of which resulted in serious injuries.
The recall could affect the ROCKET-AF results, because falsely low readings could have resulted in warfarin patients being given too high a dose, increasing their risk of bleeding. If the device caused excessive bleeding among warfarin patients, it could have given the false impression that Xarelto had a lower rate of bleeding events.
The BMJ noted that the ROCKET-AF clinical trials, used to convince the FDA to grant Xarelto approval, was already the subject of serious concerns, long before the INRatio recall was linked to the study. Many of those criticisms were focused on patients’ use of warfarin.
“Even before the recall, the ROCKET-AF trial had been criticized for the relatively short time that participants taking warfarin were in the correct therapeutic range of the drug,” The BMJ noted. “The implication of the criticism was that patients’ use of warfarin was not adequately controlled, which, if correct, would have the effect of making rivaroxaban seem safer and more effective.”
The BMJ noted that it contacted Johnson & Johnson and Bayer Healthcare, the manufacturers of Xarelto, in September, about the INRatio recall. However, Johnson & Johnson officials indicated that they were unaware of it.
Xarelto Bleeding Problems
Xarelto (rivaroxaban) is part of a new class of blood thinners introduced in recent years as a replacement for warfarin. It is most commonly prescribed to reduce the risk of blood clots and strokes among patients with atrial fibrillation or following hip or knee replacement surgery.
Known as a factor xa drug, Xarelto was designed to compete with Boehringer Ingelheim’s Pradaxa, which is another member of the same new class of medications, which are promoted as easier to use than warfarin, since they do not require consistent monitoring to maintain appropriate dosage. A third member of this new class is Eliquis, and all three medications have been aggressively promoted in direct-to-consumer advertisements in recent years.
Problems with Xarelto, Pradaxa and Eliquis have been reported due to the lack of an antidote for any of the medications at the times they were released, often leaving doctors helpless to stop bleeds that may develop among users of the blood thinners.
While users of warfarin can be given a dose of vitamin K to reduce the blood thinning effects of the medication, there were no similar reversal agents available for Pradaxa, Xarelto or Eliquis until recently.
In October, the FDA approved the use of Praxbind, a reversal agent for Pradaxa. This has been seen by many observers as a clear market advantage for Pradaxa in this lucrative treatment field, increasing the pressure on the makers of Xarelto to finalize their own reversal agent.
Portola Pharmaceuticals has said it expects to present a Xarelto reversal agent for approval this month.
Xarelto Lawsuits
Thousands of Pradaxa lawsuits,
Bayer and Johnson & Johnson are currently facing a growing number of Xarelto lawsuits filed on behalf of individuals and families throughout the U.S., alleging that the drug makers failed to adequately research the medication, warn about the bleeding risk or the lack of an effective reversal agent.
Several thousand similar Pradaxa lawsuits were filed against Boehringer Ingelheim following it’s approval, and that drug maker ultimately agreed to pay about $650 million in settlements for Pradaxa users in May 2014, with an average of about $150,000 per claim. However, additional cases continue to be filed by individuals who have suffered injuries since the date of the settlement.
There are currently about 3,000 lawsuits over Xarelto bleeding problems pending throughout the federal court system, which are currently centralized for pretrial proceedings as part of an MDL, or multidistrict litigation.
Unless Xarelto settlements are reached to resolve the litigation, the first trials are expected to begin by August 2016.
http://www.aboutlawsuits.com/xarelto-trial-concerns-90839/#sthash.wha1FrQI.dpuf
-
Xarelto Lawsuits’ Similarities To Pradaxa Lawsuits Encourage Plaintiffs
Dec 8, 2015 | Mass Tort Nexus
By Larry Bodine
BloodThinnerHelp.com reports on similarities between Xarelto and Pradaxa lawsuits, which have helped to give plaintiffs involved in current Xarelto lawsuits hope as they pursue justice. Xarelto lawsuit filings have recently exploded. Today, suits filed federally have been consolidated to form multidistrict litigation docket 2592, and number somewhere around 2,000. It has been reported that in the month of August alone, around 400 additional cases joined the MDL, and those involved expect to see these numbers continue to increase.Xarelto lawsuits are being overseen by Judge Eldon Fallon in the Eastern District of Louisiana, and have been filed against defendants Bayer AG and Janssen Pharmaceuticals, (a division of Johnson & Johnson). These cases are joined by approximately 500 others which have become part of a mass tort grouping in Philadelphia, Pennsylvania.
Bellwether trials
Judge Fallon has asked that a series of four bellwether trials be prepared to go before juries regarding the Xarelto MDL cases. These bellwether trials are currently scheduled for Spring of 2017, as trial preparations need to take place beforehand. The cases contained in the Xarelto MDL all commonly allege that the blood-thinning drug can cause episodes of dangerous, uncontrollable bleeding. In some cases, these bleeding episodes have proven fatal.
Xarelto was released to the market without a corresponding antidote. Much of the controversy surrounding the drug relates to this factor, which plaintiffs call negligent and extremely dangerous. Because it has no antidote, if a patient using Xarelto becomes injured and bleeds, physicians will be unable to get their blood to clot. In these cases, the physicians are required to resort to extreme life-saving tactics such as surgeries to drain pools of blood, or blood transfusions. Patients in these circumstances are at significant risk of losing too much blood, and of either dying or suffering from long-term health issues.
Pradaxa is a similar new-generation blood-thinner which was marketed by Boehringer Ingelheim in October of 2010. Similarly to Xarelto, shortly after its release to market, Pradaxa was surrounded by over 3,500 reports of serious adverse events. More than 750 of these reports involved the death of a Pradaxa patient. Pradaxa quickly became the subject of over 4,000 lawsuits. The evening before the trial was set to begin, however, manufacturer Boehringer Ingelheim agreed to pay $650 million to plaintiffs in Pradaxa lawsuit settlements.
Today, Xarelto plaintiffs view these facts as hopeful as their cases progress toward trial. They await settlement talks, though at this time, there have been no reports of a settlement. As those involved prepare for trial, Attorney Joseph Osborne has been attempting to ensure that everyone negatively affected by Xarelto will have the ability to investigate their legal rights. He is currently offering free legal consultations to those who have taken Xarelto and have suffered from adverse health events after doing so. It is believed that these individuals may be entitled to significant compensation.
http://www.masstortnexus.com/mass-torts-news/xarelto-lawsuits-similarities-pradaxa-lawsuits/
-
Xarelto Lawsuit Claims Man Suffers Brain Bleed
Dec 9, 2015 | Top Class Actions
By Melissa LaFreniere
A Xarelto lawsuit claims the blood thinner caused a life-threatening brain hemorrhage after the plaintiff took the drug for three months.
Plaintiff Glen S. filed a Xarelto lawsuit against pharmaceutical giants Bayer Healthcare, Johnson & Johnson, as well as its subsidiary Janssen Pharmaceuticals, for allegedly negligently misrepresenting the anticoagulant as a safe and effective medication.
According to the lawsuit, Xarelto’s manufacturers conducted marketing campaigns to promote the sale of Xarelto and “willfully deceived” patients, along with physicians and the general public, regarding the consequences of taking Xarelto.
The Xarelto lawsuit claims that by advertising Xarelto direct to consumers, patients began requesting prescriptions of the new blood thinner. The lawsuit alleges that the marketing of Xarelto “failed to disclose the need for dose adjustments, failed to disclose the need for blood monitoring, and failed to adequately disclose to patients that there is no drug, agent, or means to reverse the anticoagulation effects of Xarelto, and, that such irreversibility could have permanently disabling, life-threatening and fatal consequences.”
The Xarelto bleeding lawsuit alleges that in 2013 manufacturers spent at least $11 million on Xarelto advertising in the U.S. alone. Plaintiff Glen claims that as a result of the direct-to-consumer campaign, Xarelto reached “blockbuster status” with sales reaching $2 billion that year.
Plaintiff Glen states that this “outrageous conduct” should award him punitive damages, which is a financial award large enough that it is designed to “punish” the defendant.
Xarelto Bleeding Side Effects
The U.S. Food and Drug Administration approved Xarelto in 2011 as a blood thinner designed to treat atrial fibrillation patients and is commonly prescribed to patients to prevent blood clots after hip or knee surgery.
Manufacturers promoted Xarelto as a more convenient blood thinner when compared to Warfarin (Coumadin), which has been on the market for more than 50 years. Unlike Warfarin, Xarelto consumers were assured that there is no need for dietary restrictions or regular blood monitoring.
However, patients like Glen who suffered a bleeding event claim they were not warned that should they experience a bleed there would be no way to get it under control.
Warfarin consumers can be given a dose of vitamin k to get bleeding under control, but Xarelto patients are forced to undergo multiple blood transfusions and lengthy hospital stays because the only known way to stop the internal bleeding is to get the drug out of the system.
In its short time on the U.S. market, Xarelto has been named in thousands of FDA adverse event reports, many of those claiming the drug caused a hemorrhage-related death.
Xarelto Multidistrict Litigation
In March an order was issued that makes it unnecessary for plaintiffs to have to file an Xarelto lawsuit into a local district to wait to be transferred to the Xarelto MDL centralized in Louisiana.
Plaintiff Glen is one of hundreds who have joined the Xarelto MDL hoping to receive financial compensation from the manufacturers for allegedly failing to warn of the potentially severe Xarelto internal bleeding complications.
The Xarelto Bleeding Lawsuit is In re: Xarelto (Rivaroxaban) Products Liability Litigation, Case No. 2:15-cv-05992-EEF-MBN and MDL No. 2592 in the U.S. Court for the Eastern District of Louisiana.
http://topclassactions.com/lawsuit-settlements/lawsuit-news/242168-xarelto-lawsuit-claims-man-suffers-brain-bleed/
-
Xarelto History: What you need to know
Dec 9, 2015 | Your Xarelto Attorneys
In 2011, the U.S. Food and Drug Administration (FDA) announced that it approved the anti-clotting drug Xarelto® (rivaroxaban) to reduce the risk of stroke in people who have abnormal heart rhythm, or non-valvular atrial fibrillation. The FDA also approved Xarelto® to reduce the risk of blood clots, deep vein thrombosis, and pulmonary embolism following knee or hip replacement surgery. Xarelto® is manufactured by Janssen Pharmaceuticals, Inc., which is a subsidiary of Johnson & Johnson. Xarelto® is also co-marketed with Bayer AG.Safety of Xarelto®
According to the FDA, the safety and efficacy of the drug was evaluated in a clinical trial that was comprised of more than 14,000 patients. The trial compared Xarelto® to Warfarin, another anti-clotting drug. The trial found that Xarelto® was similar to Warfarin in its ability to prevent stroke.
Importantly, however, the trial also found that Xarelto® has many of the same side effects as other anti-clotting drugs. The most notable Xarelto® side effect is bleeding, which, in rare cases, may lead to death. Bleeding was found to be the most common adverse event reported in patients taking Xarelto®, and the risk of major bleeding was found to be similar to that of Warfarin.
Drugmakers Sought to Expand Use of Xarelto®
In 2014, Bayer AG and Johnson & Johnson sought to expand the approved uses for Xarelto®. The drugmakers wanted to market Xarelto® as a drug that could prevent new heart attacks and strokes, and even death. The drugmakers also wanted to market the drug as having the ability to prevent clogging of heart stents.The FDA, however, denied the drugmakers’ request. Ultimately, the FDA found that clinical data was not strong enough to support the proposed claims.
In 2013 and 2014, the FDA required that Xarelto® drugmakers include boxed warnings. In 2013, the FDA required that Xarelto® include a warning that premature discontinuation of Xarelto® increases the risk of thrombotic events, and spinal/epidural hematoma. And in 2014, the FDA required that the drug must contain a warning that it can cause internal bleeding. The warning must also state that a specific antidote is not available for Xarelto®.Contact a Xarelto® Lawsuit Attorney
Since the drug has been approved by the FDA, thousands of individuals have suffered adverse side effects from taking Xarelto®. As a result of these Xarelto® side effects, more than a 1,000 people have filed lawsuits against the drugmakers claiming that they manufactured a defective drug and failed to warn the public about the drug’s possible dangers. The first few lawsuits are expected to go to trial in the beginning of 2017.
If you experienced a serious side effect while taking Xarelto®, reach out to an experienced Xarelto® attorney today to find out how to protect your legal rights. Your Xarelto® lawyer can also help you file a claim within the statute of limitations to ensure you have the highest chance of success.
http://my-xareltolawsuit.com/history-of-xarelto/
-
Xarelto Side Effects & Lawsuit Information
Dec 11, 2015 | Active Health News
Xarelto is a blood-thinning drug, or anticoagulant. The U.S. Food and Drug Administration (FDA) approved Xarelto in July 2011, and its sales have steadily grown since then. While bleeding is a common complication associated with anticoagulants, it has been alleged that Xarelto is more dangerous than traditional blood thinners because no antidote exists to reverse its blood-thinning side effects.
Xarelto Bleeding Lawsuit
Many patients who suffered Xarelto bleeding-related injuries, strokes, pulmonary embolisms, deep vein thrombosis, and heart attacks have filed a Xarelto bleeding lawsuit. Most of these Xarelto bleeding lawsuits are product liability bleed lawsuits against the manufacturers Johnson & Johnson and Janssen Pharmaceuticals. The manufacturers of other, similar blood-thinning drugs face similar Xarelto bleeding lawsuits. Thousands have filed Xarelto bleeding lawsuits against Boehringer Ingelheim. These lawsuits are quite similar and more numerous, and may provide an early glimpse of the future of Xarelto bleeding lawsuits.
While people file lawsuits for many reasons, the most prominent reason is to recover financial compensation for a patient’s injuries. Xarelto injuries can require lengthy hospitalization, significant long-term health care costs, and substantial time away from work. Product liability Xarelto bleeding lawsuits exist in large part to shift the burden of these costs to manufacturers. For many families, filing a Xarelto bleeding lawsuit can be the difference between financial hardship and making ends meet.
Xarelto Bleeding Attorney
Patients who are injured from Xarelto side effects should consult with a Xarelto bleeding attorney to learn more about their legal options. The Rottenstein Law Group is a great Xarelto bleeding attorney who are reviewing claims of uncontrollable Xarelto bleeding side effects that might give rise to Xarelto bleeding lawsuits.
Bayer and Johnson & Johnson’s Janssen Pharmaceuticals, Inc. are facing several xarelto lawsuits from a leading Xarelto bleeding attorney alleging that Xarelto side effects are dangerous and defective. Plaintiffs in the Xarelto bleeding lawsuit allege serious and fatal injuries, including cerebral hemorrhaging and gastrointestinal bleeds, from use of the drug Xarelto. If you or a loved one suffered from one or more of these Xarelto side effects while taking Xarelto, and you wish to discuss your case with a Xarelto bleeding attorney.
What are the Side Effects of Xarelto?
Xarelto Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects of Xarelto when taking this medication.
Xarelto side effects include easy bruising, unusual bleeding (nose, mouth, vagina, or rectum), bleeding from wounds or needle injections, any bleeding that will not stop. Heavy menstrual periods is a dangerous Xarelto side effect. Other Xarelto side effects include black or bloody stools, coughing up blood or vomit that looks like coffee grounds.
Less serious Xarelto side effects may include: muscle pain, itching and pain in arms or legs. However, the most common adverse Xarelto side effects are bleeding complications, including major bleeding events. Fainting, itching, and muscle spasms have been reported. Some blood thinning antibiotics, antifungal medications, anticoagulants, blood thinners, NSAIDs, and aspirin may have adverse interactions and cause further Xarelto side effects.
http://activehealthnews.com/xarelto-side-effects-lawsuit-information/
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Plaintiff Attorney Press Releases
Plaintiff Attorney Blog Posts
Full Text of Articles Below
Add recipients
Suggested